普洛药业：丁二磺酸腺苷蛋氨酸肠溶片目前在京津冀“3+N”联盟和广东联盟中已中标，正处于快速拓展市场中

Core Viewpoint - The company has successfully launched its product, Dihydrosilyl Adenosine Methionine Enteric-Coated Tablets, which is recognized for its clear pharmacological mechanism, high safety, and good clinical efficacy, positioning it as a preferred treatment for liver diseases [2]. Company Summary - The product received approval for market launch in November 2024 and is currently expanding its market presence [2]. - The company has secured bids in the Beijing-Tianjin-Hebei "3+N" alliance and the Guangdong alliance, indicating a strategic approach to market penetration [2].